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Sentinel lymph node (SLN) examination is a standard in breast cancer patients, with
several methods employed along its 20 years history, the last one represented by one-
step nucleic acid amplification (OSNA). The latter is a intra-operative molecular assay
searching for CK19 mRNA as a surrogate of metastatic cells. Our 3 years experience with
OSNA (1122 patients) showed results overlapping those recorded in the same institution
with a morphological evaluation (930 patients) of SLN. In detail, the data of OSNA were
almost identical to those observed with standard post-operative procedure in terms of
patients with positive SLN (30%) and micrometastatic/macrometastatic involvement of
SLN (respectively, 38–45 and 62–55%). By contrast, when OSNA was compared to the
standard intraoperatory procedure, it was superior in terms of accuracy, prompting the
use of this molecular assay as a very valid, and reproducible for intra-operative evaluation
of SLN. Further possibilities prompting the use of OSNA range from adhesion to quality
control programs, saving of medical time, ability to predict, during surgery, additional
nodal metastasis, and molecular bio-banking.
Keywords: breast cancer, sentinel node examination, molecular analysis, morphological analysis, permanent
sections, frozen section, accuracy
Background
Sentinel lymph node (SLN) evaluation is a standard staging procedure in breast cancer patients with
clinically negative axilla (1–4). Recent studies have suggested that patients with micro-metastatic
SLN can avoid complete nodal dissection (5–7). By contrast, a conservative surgical approach of
patients with macrometastatic SLN is highly debated and still unaddressed (8–10). Great effort is
thus requested to pathologists in the evaluation and quantification of the tumor burden in SLN.
Several methods have been employed to examine SLN in a 20-year long history, all based
on two different approaches. The first one is an improvement of the standard histopathological
examination: SLN is evaluated using consecutive post-operatory permanent sections (PO-PS) taken
from formalin-fixed paraffin-embedded tissue (1). However, the number of sections analyzed is
very variable, up to specimen exhaustion (11). This approach guarantees an optimal morphological
detail and it can be further supplemented by additional studies (immunohistochemical analysis, case
sharing, etc.). An obvious limitation of this method is that sentinel-positive patients are subjected
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to a second surgical intervention. To overcome this drawback, an
intraoperatory examination using frozen sections (IO-FS) of SLN
(12) was introduced. However, the latter method may be limited
by a lower accuracy (13), by the intraoperatory time dedicated to
the procedure, and by the increased need of technical and med-
ical resources. Also, the use of additional tools, such as imprint
cytology or rapid immunohistochemistry, is not standardized and
reliable enough to fill the accuracy gap between IO-FS and PO-
PS (14, 15). Finally, both IO-FS and PO-PS SNL examination
are characterized by a partial examination of the whole node.
Indeed, the great majority of the sections are eliminated through
the cutting procedure.
A completely different methodological approach is the search
of a molecular fingerprint as surrogate marker of metastatic cells.
Earlier studies suggested the use of cytokeratin 19 (CK19), mam-
maglobin, andmaspin (16, 17). Indeed, when the abovemolecular
analyses were compared to extensive morphologic examination
of SLN, their sensitivity was >90% with almost absolute speci-
ficity. Accordingly, a molecular assay named one-step nucleic
acid amplification (OSNA, SysmexCorporation, Kobe, Japan) was
proposed, validated, and standardized in the examination of SLN
in patients affected by breast cancer (18–20). OSNA quantifies the
number of CK19 mRNA copies in the whole nodal homogenate.
Table S1 in Supplementary Material illustrates the comparison of
criteria used to evaluate SLN status by this method and by that
based on the tumor size resulting from the TNM staging system.
In this paper, we report our 3 years experience with OSNA in
patients affected by breast cancer and we discuss the diagnos-
tic performance with costs analysis, turnaround times (TATs),
advantages, and limitations of this molecular assay.
OSNA Molecular Assay at Humanitas
Cancer Center
Since the introduction of OSNA, 1122 patients underwent SLN
procedure at our Institution, with the number of examined nodes
ranging between 1 and 4 per individual patient (mean: 1.2). A
positive (metastatic) SLN was seen in 322 (29%) patients. The
nodal disease was classified as 2+, macrometastasis, in 177 cases
(55%) and 1+, micrometastsis, in 145 cases (45%). Results are
reported in Table 1.
As shown in Table 2, the vast majority of SLN 2+ patients
underwent a subsequent complete axillary lymph-node dissection
(ALND) where 76 (43%) patients were found to have one or more
additional metastatic nodes. Among the group of SLN 1+ 97
patients underwent ALND with a significantly lower proportion
of cases (15, 15%) showing additional metastasis.
Of 91 patients with additionalmetastasis after complete axillary
dissection, 23 (25%) showed >3 metastatic nodes; more specifi-
cally 22/23 cases had a previous OSNA report of SLN 2+ with a
single case scoring 1+.
Overall, data generated by OSNA were then compared to our
previous experience with SLN examination using either PO-PS
or IO-FS (21). No other variables except the change in the tech-
nique affected this study because the teams involved (Pathol-
ogy, Surgery, and Nuclear Medicine) were the same. Results are
TABLE 1 | SLN status as evaluated by OSNA in patients affected by breast
cancer.
OSNA
first year
(no. 437 pts)
OSNA
second year
(no. 366 pts)
OSNA
third year
(no. 319 pts)
OSNA
(total)
(no. 1122 pts)
SLN status
Negative 318 (73%) 263 (72%) 219 (69%) 800 (71%)
Positive 119 (27%) 103 (28%) 100 (31%) 322 (29%)
2+ 81 44 52 177
1+ 38 59 48 145
Bold font highlights positive cases.
TABLE 2 |Patients with additional nodal metastasis in the axillary dissection
after a positive OSNA report.
First
year
Second
year
Third
year
Total
Patients with additional nodal mets
(after SLN 2+)
35/81
(43%)
21/42
(50%)
20/52
(38%)
76/175a
(43%)
Patients with additional nodal mets
(after SLN 1+)
6/36
(17%)
6/41
(15%)
3/20
(15%)
15/97a
(15%)
a2 patients after 2+ and 48 after 1+ refused complete nodal dissection following data
from Galimberti et al. (5).
illustrated in Table S2 in Supplementary Material. Among the
three series, the accuracy in the detection of metastatic nodes was
significantly better when using PO-PS (30%) and OSNA (29%)
as compared to IO-FS (22%) (p= 0.01). Similarly, the accuracy
rate in the detection of macro- and micro-metastasis using IO-
FS was significantly different as compared to other techniques
(p< 0.01). These resultsmay be explained by themore standardiz-
able and reproducible protocols of OSNA and PO-PS techniques
as compared to IO-FS. Indeed, the latter method is intrinsically
more dependent on the experience of the operator (thickness and
number of sections, integrity of sections, manual ability of the
technician, etc.).
The predictive value of additional nodal mets of a positive
sentinel node in patients with axillary dissection showed more
homogeneous data among the three techniques. The values ranged
between 31 and 33%, with OSNA and PO-PS series showing again
the most overlapping results. OSNA 2+ and macromets yielded,
as expected, a higher number of additional mets in the axillary
dissection, as compared to OSNA 1+ and micromets.
OSNA Molecular Assay: Literature
Overview
The reliability of the OSNA assay has been repeatedly demon-
strated in the literature. High specificity, sensitivity, accuracy,
positive, and negative predictive values have validated OSNA as
a very good and objective method to investigate the SLN status
in breast cancer patients (22). As shown in Table S3 in Supple-
mentary Material, some differences have been reported as to the
rate of positive nodes and the distribution of OSNA scores (–,
1+, 2+), likely related to differences in the series. For example,
an accurate clinical, radiological, and cytological pre-operative
evaluation of the axilla may permit a diagnosis of metastatic
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node (macrometastasis), which is not further subjected to the
molecular assay, thus increasing the relative number of OSNA
cases scoring 1+. However, all the studies report similar results
in the percentage of additional nodal mets, with values close to
40% for macromets and to 16% for micromets.
Turnaround Time and Cost Analysis
The average TAT per single procedure was 48min. for OSNA and
50min for IO-FS. More specifically, the allocated time for the
pathologist was 5min for OSNA and 45min with IO-FS. The allo-
cated time for the technician was similar in both the procedures
(50min). In terms of consumables and equipment OSNA were
more expensive than IO-FS while in terms of human resources
IO-FS were more expensive than OSNA. In keeping with other
reports based on the molecular evaluation of SLN (23, 24), during
the first year, we annotated a cost of 270AC for a single procedure.
During the first year of OSNA experience, all SLNs were eval-
uated regardless the number of scheduled procedures or whether
the node was macroscopically metastatic. During the second and
third year, we decided to perform the molecular assay if at least
four patients were scheduled for SLN procedure and never in
cases of grossly metastatic nodes. This means that we performed
IO-FS whenever up to three SNL procedures were scheduled
(mixed regimen). Indeed, a retrospective cost analysis showed us
that the OSNA procedure for a single SLN/day was much more
expensive than the same single procedure conducted in a surgical
session with four or more scheduled SLNs. This is because a fixed
charge is due for the activation of the OSNA equipment. As a
consequence of this selection policy in the use of the molecular
assay, our costs were significantly reduced. However, cases with
up to three procedures/day were conducted using IO-FS with a
negative impact on the medical time allocated to the procedure
(up to 3 h/day).
Also, interesting is the cost comparison between OSNA and
SNL examination conducted on permanent sections. Two studies
coming from the UK, one conducted in a large district general
hospital (23) and the other by the University and the Health
Economic Consortium of York (25) showed that the savings in
terms of reduced secondary surgeries and bed occupancy, could
potentially be 150AC per patients.
Advantages and Disadvantages
Provided that OSNA is more standardized than IO-FS and at least
equally accurate, the most significant advantage is the medical
time saved during the procedure. From a practical point of view,
having adopted OSNA as the method to examine SLN when at
least four procedures are scheduled, pathologists in charge will
save at least 2.5 h during each surgical session. Having had ses-
sions up to nine procedures, this meant a full day of a working
pathologist. A further advantage is the possibility to perform in the
same introperatory time a IO-FS and aOSNAprocedure, provided
to have two technicians, a single pathologist, a cryostat and a
OSNA equipment. A third aspect is the possibility to evaluate
more than one SLN (up to four) in the same run. This might
even contemplate the possibility to cumulate nodes from different
patients; this is quite unusual at least in our experience but it
may occur in centers with multiple synchronous surgical breast
procedures. A more common occurrence (about 10% of the cases
in our series) is the synchronous examination of more than one
node for a single patient. Needless to say, such a condition is not
feasible with a IO-FS approach. Finally, the post-OSNA residual
node homogenate is a bank of biological molecules and a potential
source of material for future investigations. Last, but not least,
a quality control program can be easily undertaken among labs
using this molecular technique.
Among disadvantages, cost and TAT have been already dis-
cussed. The existence of CK19 negative breast tumor may have
a negative impact on the specificity of the OSNA procedure.
This possibility was estimated to occur in 2–3% of breast cancer
evaluated using immunohistochemistry. However, Pegolo et al.
(26) showed that cases with negative CK19 immunostaining had
a significant CK19 expression at mRNA level. We have also
adopted and recommend the use of intra-operative cytological
smear before starting an OSNA procedure to avoid false-negative
cases. Benign epithelial inclusions and epithelial cells displace-
ments might also be the cause of false-positive results (27, 28);
however, the low levels of CK19 mRNA copies in these particular
cases are reported to be below the cutoff of an OSNA positive
test. However, in IO-FS, these inclusions/cell displacements might
be very difficult to be differentiated from micro-metastasis or
isolated tumor cells, as well as from intra-capsular nevi.
Tumor Burden and Prediction of Axillary
Status
One of the most exciting advantage of OSNA over conventional
IO-FS examination of SLN is that the former provides a value
in terms of mRNA copy number (representative of the tumoral
burden), which can been used to predict additional mets in
ALND. Importantly, several investigators have already developed
nomograms associated with ALND mets. However, these nomo-
grams can be applied after the histological examination of breast
cancer (29) and not during the intraoperatory time. By contrast,
OSNA-based nomograms (30, 31 and Di Filippo, personal com-
munication) may be used during the intraoperatory time and as
such data they can be immediately used to re-orient the surgical
management of the case (to performor not the axillary dissection).
Conclusion
Themolecular evaluation of SLN in breast cancer patients appears
as a frontier currently explored by pathologists. When we were
firstly exposed to this technique ourmajor concernwas to perform
a diagnosis without the fundamental aid of the microscope nor of
the human eye. However, after 3 years of experience, we are much
more confident in the technique which showed reproducible
results over 3 years in more than 1000 SLN analyzed. Importantly,
when OSNA was compared to the other standard intraoperatory
procedure (IO-FS), it was superior in terms of accuracy. We
therefore endorse OSNA as a very valid and reproducible assay
for SLN.
The molecular evaluation of SLN can be very fruitful. Stan-
dardization and reproducibility are very important issues in a
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pathology lab and they can be easily and quickly obtained. The
possibility to adhere to quality control programs is another not
negligible opportunity. In addition, the saving of medical time is
also and obviously especially important. Further, golden oppor-
tunities of this frontier are to be expected. The possibility to
predict, during surgery (32–36), additional nodal mets would
address the critical issue raised by the ACOSG Z0011 study (8);
while mRNA analysis using gene expression from metastatic foci
would hopefully provide predictive information on the tumor
behavior.
Supplementary Material
The SupplementaryMaterial for this article can be found online at
http://journal.frontiersin.org/article/10.3389/fmed.2015.00037/
abstract
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